A practical guide to the handling and administration of talimogene laherparepvec in Europe

Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a)...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Kevin J, Michielin, Olivier, Malvehy, Josep, Pezzani Grüter, Isabella, Grove, Lorna, Frauchiger, Anna Lisa, Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546812/
https://www.ncbi.nlm.nih.gov/pubmed/28814886
http://dx.doi.org/10.2147/OTT.S133699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546812/
https://www.ncbi.nlm.nih.gov/pubmed/28814886
http://dx.doi.org/10.2147/OTT.S133699

Ejemplares similares